Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days. Issue 4 (11th January 2023)

• Record Type: Journal Article
• Authors: Debette‐Gratien, Marilyne; François, Sandrine; Chevalier, Catherine; Alain, Sophie; Carrier, Paul; Rigaud, Céline; Abraham, Bruno; Burgevin, Anne‐Laure; Courat, Laurent; Debenes, Bernard; Koffi, Joseph; Caux‐Nussbaum, Elisabeth; Zattoni‐Leroy, Juliette; Feuillet‐Sow, Gaëlle; Dumont, Quentin; Nubukpo, Philippe; Loustaud‐Ratti, Véronique
• Is Part Of: Journal of viral hepatitis. Volume 30:Issue 4(2023)
• Page Start: 355
• Page End: 361
• Publication Date: 2023-01-11
• Subjects: drug users -- HCV elimination -- HCV screening -- liver elastometry -- point‐of‐care HCV RNA assay; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.13798
• Languages: English
• ISSNs: 1352-0504

Abstract

Abstract: According to the French recommendations, the elimination of the hepatitis C virus by 2025 could be a realistic public health goal. Screening policies are being intensified, and access to treatment is promoted for patients who escape the usual care pathway. The 'Scanvir' program is an original strategy based on dedicated screening days, as part of the 'test, treat and cure HCV' event in addiction care centers in a French region, during which innovative screening technologies (RDTs, FibroScan® and point‐of‐care HCV RNA testing) are brought on site and access to a multidisciplinary team is offered. A total of 392 patients attended the 67 regional Scanvir sessions: 31.6% were HCV Ab‐positive and 66% of them were HCV RNA‐positive. Treatment was initiated in 79.3% of the patients. RDTs were accepted by 62% of the PWIDs (including those who already knew their status) and FibroScan® by 99.5% of the patients. 80% of the viremic patients started their treatment on site and are now cured or still under treatment. Advanced fibrosis evaluated by FibroScan® (LSM > 8 KPa) was suspected in 13.4% and 14.1% of the global and the HCV population, respectively. Scanvir is an efficient strategy for HCV elimination based on dedicated days aimed at increasing cost‐effectiveness and offering a multidisciplinary service while saving human care resources. It is an exportable strategy that also offers comprehensive screening of associated chronic liver diseases via the elastometry device and interviews.